Using Cox regression models, T2 predicted death in AL amyloidosis (hazard ratio, HR, 1.48, 95% CI 1.20–1.82) and remained significant after adjusting for EF and ECV (HR 1.31, 95% CI 1.04–1.66) (Abstract 1, Figure 2).

Conclusion Patients with AL amyloidosis have a worse prognosis compared to ATTR despite having less cardiac amyloid infiltration. T2 was significantly higher in untreated AL amyloidosis consistent with oedema, and was an independent predictor of prognosis. The higher ECV in ATTR was consistent with higher amyloid infiltration. These findings highlight the unique role of CMR with multiparametric mapping for characterising the cardiac effects of systemic amyloidosis and risk stratification in this population.

002

SUDDEN CARDIAC DEATH RISK STRATIFICATION IN PATIENTS WITH MILD DILATED CARDIOMYOPATHY

¹Brian P Halliday, ¹Ankur Gulati, ¹Aamir Ali, ¹Kaushik Guha, ²Simon Newsome, ¹Monika Arzanasikaite, ¹Vassilios S Vassiliou, ¹Amrit Lota, ¹Upasana Tayal, ¹Zohra Khaliq, ¹Cemil Izgi, ¹Francisco Alpendurada, ^{1,3}John GF Cleland, ¹Dudley J Pennell, ¹Sanjay K Prasad. ¹NIHR Biomedical Research Unit, Cardiovascular Magnetic Resonance Unit and Department of Cardiology, Royal Brompton Hospital, UK; ²London School of Hygiene and Tropical Medicine, UK; ³Robertson Centre for Biostatistics, University of Glasgow, UK

10.1136/heartjnl-2017-311399.2

Background The DANISH trial emphasised that the selection of patients with dilated cardiomyopathy (DCM) for implantable cardioverter defibrillators (ICD) needs to be improved. Registries demonstrate that the major burden of sudden cardiac death (SCD) occurs in those with a left ventricular ejection fraction (LVEF) >35%. Those at high-risk of SCD with milder reductions in LVEF may gain greater quality-adjusted life years from successful ICD therapy compared to those with more severe reductions, due to a lower risk of death from competing non-sudden causes. Variables that identify patients with milder reductions in LVEF at high-risk of SCD are required.

Methods We prospectively investigated the utility of mid-wall late gadolinium enhancement (LGE) cardiovascular magnetic resonance (CMR) to predict SCD and aborted SCD in consecutive patients with DCM and LVEF >40% seen in our cardiomyopathy service or referred for CMR between 2000 and 2011. Those with potential pre-existing indications for ICD implantation were excluded. The presence of LGE was determined by a specialist blinded to clinical data. A panel blinded to CMR data adjudicated end-point occurrences.

Results Of 399 patients (145 women, median age 50 years, median LVEF 50%) followed for a median of 4.6 years, 18 of 101 (17.8%) with LGE reached the pre-specified end-point, compared to 7 of 298 (2.3%) without (HR 9.2; 95% CI 3.9–21.8; $p<0.0001$) (Figure 1). Nine patients (8.9%) with LGE compared to 6 (2.0%) without (HR 4.9; 95% CI 1.8–13.5; $p=0.002$) died suddenly, whilst 10 patients (9.9%) with LGE compared to 1 (0.3%) without (HR 34.8; 95% CI 4.6–266.6; $p<0.001$) had aborted SCD. Following adjustment based on propensity score, LGE predicted the composite end-point (HR 8.0; 95% CI 3.3–19.5; $p<0.0001$), SCD (HR 4.6; 95% CI 1.6–13.1; $p=0.005$) and aborted SCD (HR 32.9; 95% CI 4.3–249.9; $p<0.001$). Estimated hazard ratios for the primary end-point for patients with a LGE extent of 0%–2.5%, 2.5%–5% and >5% compared to those without LGE were 10.6

(95%CI 3.9–29.4), 4.9 (95% CI 1.3–18.9) and 11.8 (95% CI 4.3–32.3).

Conclusion Mid-wall LGE identifies patients with DCM and a LVEF >40% with an 8-fold increased risk of SCD and aborted SCD, who may benefit from ICD implantation.

Acknowledgements BPH is supported by a British Heart Foundation Clinical Research Training Fellowship. The study has also been supported by the Alexander Jansons Foundation and CORDA.

003

PRECISE PHENOTYPING WITH CMR IDENTIFIES MODERATE ALCOHOL CONSUMPTION AS AN IMPORTANT PHENOTYPIC MODIFIER OF TITIN CARDIOMYOPATHY

^{1,2}U Tayal, ³S Newsome, ¹N Whiffin, ²R Buchan, ²R Walsh, ^{1,2}PJ Barton, ^{1,2}JS Ware, ^{1,4}SA Cook, ^{1,2}SK Prasad. ¹National Heart Lung Institute, Imperial College London, UK; ²Royal Brompton Hospital, London, UK; ³Department of Medical Statistics, London School of Hygiene and Tropical Medicine, UK; ⁴Duke National University Hospital, Singapore

10.1136/heartjnl-2017-311399.3

Background Truncating variants in titin (TTNtv) are the commonest genetic cause of dilated cardiomyopathy (DCM). They are notable for variable penetrance and expressivity, suggestive of environmental or genetic modifiers.

Purpose Undertake deep phenotyping by cardiac MRI (CMR) to evaluate alcohol and hypertension as phenotypic modifiers of TTNtv cardiomyopathy.

Methods Prospectively recruited DCM patients underwent comprehensive clinical evaluation, CMR with late-gadolinium enhancement and TTN sequencing.

Results Overall, 733 subjects, mean age 53.4 ± 14.4 years, 476 men (65.0%) were recruited. TTNtv were found in 82 (11.2%) patients.

Abstract 003 Table 1 Regression analysis evaluating TTNtv and alcohol excess as predictors of LVEF

Variable	Unadjusted analysis			Adjusted analysis*		
	Estimate	95% confidence interval	P value	Estimate	95% confidence interval	P value
	(change in LVEF, %)			(change in LVEF, %)		
Baseline: No TTNtv or alcohol excess	0	-	-	0	-	-
TTNtv, no alcohol excess	0.06	-3.0 to 3.1	0.97	-0.3	-3.2 to 2.7	0.85
Alcohol excess, no TTNtv	-2.1	-4.7 to 0.5	0.12	-0.6	-3.2 to 1.9	0.61
TTNtv and alcohol excess	-11.8	-18.6 to -5.0	<0.001	-15.4	-21.9 to -8.8	<0.0001
TTNtv*Alcohol excess interaction§	-9.7	-17.5 to -1.9	0.02	-14.4	-21.9 to -7.0	0.0001

Table shows unadjusted univariable and adjusted multivariable analyses of the effect of TTNtv and alcohol excess on baseline left ventricular ejection fraction.

*Adjusted for gender, a family history of DCM, a history of atrial fibrillation and the presence of mid wall fibrosis (late gadolinium enhancement on CMR) and NYHA class.

§ i.e. the effect of TTNtv and alcohol excess compared to either TTNtv alone or alcohol excess alone.

LVEF by TTN and alcohol status

Abstract 003 Figure 1 Boxplot showing the change in left ventricular ejection fraction by TTNv and alcohol status. LVEF= left ventricular ejection fraction. TTN+/- = presence or absence of truncating variants in TTN. EtOH+/- = presence or absence of history of excess alcohol consumption.

Patients with a history of alcohol excess (n=114, 15.6%) were more likely to be male (n=107 (93.9%) vs n=369 (59.6%), $p<0.0001$), have lower biventricular function (left/right ventricular ejection fraction; LVEF 36.3% vs 39.5%, $p=0.01$; RVEF 47.4% vs 52.5%, $p<0.0001$) and showed a trend to increased mid wall fibrosis (n=49 (43.0%) vs n=207 (33.4%), $p=0.05$) compared to patients without alcohol excess. There was no difference between groups in age at recruitment.

Patients with TTNv and a history of alcohol excess (n=13) had a lower mean LVEF compared to patients with TTNv without a history of alcohol excess (n=69) ($27.7\% \pm 12.7$ vs $39.5\% \pm 13.1$, $p=0.005$) (Figure 1). There was no difference in LVEF between TTNv patients with a history of hypertension (n=10) and TTNv patients without (n=72) (37.7% vs 37.6% , $p=0.94$).

While TTNv, a history of alcohol excess or hypertension in isolation did not predict LVEF, the combination of TTNv and a history of alcohol excess was associated with a 15.4% reduction in LVEF (95% CI -21.9 to -8.8%) compared to a patient without either risk factor ($p<0.0001$), independently of other predictors of LVEF (gender, NYHA class, mid-wall fibrosis, atrial fibrillation and a family history of DCM) (Table 1). There was no significant interaction between TTNv and hypertension (Table 2).

Conclusions These data demonstrate the potential of using CMR to study cardiovascular endophenotypes of genetic DCM. We identify a novel gene-environmental interaction between TTNv and alcohol that prompts genetic studies in DCM in the context of high alcohol intake.

Abstract 003 Table 2 Regression analysis evaluating TTNv and hypertension as predictors of LVEF

Variable	Unadjusted analysis			Adjusted analysis*		
	Estimate (change in LVEF, %)	95% confidence intervals	P value	Estimate (change in LVEF,%)	95% confidence intervals	P value
Baseline: No TTNv or hypertension	0	-	-	0	-	-
TTNv, no hypertension	-1.6	-4.7 to 1.5	0.31	-2.4	-5.4 to 3.6	0.11
Hypertension, no TTNv	-0.4	-2.5 to 1.7	0.71	1.7	-0.3 to 3.6	0.10
TTNv and hypertension	-1.6	-9.4 to 6.2	0.70	1.4	-5.8 to 8.7	0.70
TTNv*hypertension interaction§	0.5	-8.0 to 8.9	0.92	2.2	-5.7 to 10.1	0.58

Table shows unadjusted univariable and adjusted multivariable analyses of the effect of TTNv and hypertension on baseline left ventricular ejection fraction.

*Adjusted for gender, a family history of DCM, a history of atrial fibrillation and the presence of mid wall fibrosis (late gadolinium enhancement on CMR) and NYHA class.

§ i.e. the effect of TTNv and hypertension compared to either TTNv alone or hypertension alone.